{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:32:01Z","timestamp":1793140321792,"version":"4.5.0"},"reference-count":70,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T00:00:00Z","timestamp":1644192000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Hepatology"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>HCV cure reduces but does not eliminate the risk of HCC. HCC surveillance is recommended in populations where the incidence exceeds 1.5% per year. In cirrhosis, HCC surveillance should continue after HCV cure, although it is uncertain if this should be indefinite. For patients with advanced fibrosis (F3), guidelines are inconsistent in their recommendations. We evaluated the incidence of HCC after HCV cure among patients with F3 fibrosis or cirrhosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Approach and Results<\/jats:title>\n                    <jats:p>This systematic review and meta\u2010analysis identified 44 studies (107,548 person\u2010years of follow\u2010up) assessing the incidence of HCC after HCV cure among patients with F3 fibrosis or cirrhosis. The incidence of HCC was 2.1 per 100 person\u2010years (95% CI, 1.9\u20132.4) among patients with cirrhosis and 0.5 per 100 person\u2010years (95% CI, 0.3\u20130.7) among patients with F3 fibrosis. In a meta\u2010regression analysis among patients with cirrhosis, older age (adjusted rate ratio [aRR] per 10\u2010year increase in mean\/median age, 1.32; 95% CI, 1.00\u20131.73) and prior decompensation (aRR per 10% increase in the proportion of patients with prior decompensation, 1.06; 95% CI, 1.01\u20131.12) were associated with an increased incidence of HCC. Longer follow\u2010up after HCV cure was associated with a decreased incidence of HCC (aRR per year increase in mean\/median follow\u2010up, 0.87; 95% CI, 0.79\u20130.96).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Among patients with cirrhosis, the incidence of HCC decreases over time after HCV cure and is lowest in patients with younger age and compensated cirrhosis. The substantially lower incidence in F3 fibrosis is below the recommended threshold for cost\u2010effective screening. The results should encourage the development of validated predictive models that better identify at\u2010risk individuals, especially among patients with F3 fibrosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/hep.32341","type":"journal-article","created":{"date-parts":[[2022,1,14]],"date-time":"2022-01-14T12:24:23Z","timestamp":1642163063000},"page":"139-154","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":115,"title":["HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: A meta\u2010analysis"],"prefix":"10.1097","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3031-5655","authenticated-orcid":false,"given":"Ian","family":"Lockart","sequence":"first","affiliation":[{"name":"Faculty of Medicine,St. Vincent's Clinical School,University of New South Wales,Sydney,New South Wales,Australia"},{"name":"St. Vincent\u2019s Hospital,Sydney,New South Wales,Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8711-5454","authenticated-orcid":false,"given":"Malcolm G. H.","family":"Yeo","sequence":"additional","affiliation":[{"name":"Faculty of Medicine,St. Vincent's Clinical School,University of New South Wales,Sydney,New South Wales,Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2212-2028","authenticated-orcid":false,"given":"Behzad","family":"Hajarizadeh","sequence":"additional","affiliation":[{"name":"The Kirby Institute,University of New South Wales,Sydney,New South Wales,Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4741-2622","authenticated-orcid":false,"given":"Gregory\u00a0J.","family":"Dore","sequence":"additional","affiliation":[{"name":"St. Vincent\u2019s Hospital,Sydney,New South Wales,Australia"},{"name":"The Kirby Institute,University of New South Wales,Sydney,New South Wales,Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5551-6811","authenticated-orcid":false,"given":"Mark","family":"Danta","sequence":"additional","affiliation":[{"name":"Faculty of Medicine,St. Vincent's Clinical School,University of New South Wales,Sydney,New South Wales,Australia"},{"name":"St. Vincent\u2019s Hospital,Sydney,New South Wales,Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,2,7]]},"reference":[{"issue":"10207","key":"hep32341-bib-0002-20250824","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S0140-6736(19)32320-7","article-title":"Hepatitis C","volume":"394","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"hep32341-bib-0003-20250824","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jhep.2017.08.030","article-title":"HCV eradication induced by direct\u2010acting antiviral agents reduces the risk of hepatocellular carcinoma","volume":"68","year":"2018","journal-title":"J Hepatol"},{"issue":"1","key":"hep32341-bib-0004-20250824","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"Management of hepatocellular carcinoma","volume":"69","year":"2018","journal-title":"J Hepatol"},{"issue":"2","key":"hep32341-bib-0005-20250824","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/hep.29913","article-title":"Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases","volume":"68","year":"2018","journal-title":"Hepatology"},{"issue":"5","key":"hep32341-bib-0006-20250824","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.jhep.2020.12.029","article-title":"We need stronger evidence for (or against) hepatocellular carcinoma surveillance","volume":"74","year":"2021","journal-title":"J Hepatol"},{"issue":"2","key":"hep32341-bib-0007-20250824","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","article-title":"EASL recommendations on treatment of hepatitis C 2018","volume":"69","year":"2018","journal-title":"J Hepatol"},{"issue":"2","key":"hep32341-bib-0008-20250824","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/hep.31060","article-title":"Hepatitis C guidance 2019 update: American Association for the Study of Liver Diseases\u2010Infectious Diseases Society of America recommendations for testing, managing, and treating hepatitis C virus infection","volume":"71","year":"2020","journal-title":"Hepatology"},{"issue":"1","key":"hep32341-bib-0009-20250824","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/hep.30823","article-title":"Long\u2010term risk of hepatocellular carcinoma in HCV patients treated with direct acting antiviral agents","volume":"71","year":"2020","journal-title":"Hepatology"},{"issue":"4","key":"hep32341-bib-0010-20250824","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta\u2010analyses: the PRISMA statement","volume":"151","year":"2009","journal-title":"Ann Intern Med"},{"issue":"7414","key":"hep32341-bib-0012-20250824","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta\u2010analyses","volume":"327","year":"2003","journal-title":"BMJ"},{"issue":"12","key":"hep32341-bib-0013-20250824","article-title":"Factors associated with hepatocellular carcinoma occurrence after HCV eradication in patients without cirrhosis or with compensated cirrhosis","volume":"15","year":"2020","journal-title":"PLoS One"},{"issue":"2","key":"hep32341-bib-0014-20250824","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1093\/cid\/cit234","article-title":"A risk for hepatocellular carcinoma persists long\u2010term after sustained virologic response in patients with hepatitis C\u2013associated liver cirrhosis","volume":"57","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"6","key":"hep32341-bib-0015-20250824","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/j.jhep.2020.05.052","article-title":"Personalized surveillance for hepatocellular carcinoma in cirrhosis\u2014using machine learning adapted to HCV status","volume":"73","year":"2020","journal-title":"J Hepatol"},{"issue":"5","key":"hep32341-bib-0016-20250824","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1111\/liv.14700","article-title":"Suboptimal accuracy of GES score to stratify post\u2010SVR HCC risk in a single center cohort of European cirrhotics infected with any HCV genotype","volume":"41","year":"2021","journal-title":"Liver Int"},{"issue":"3","key":"hep32341-bib-0017-20250824","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/hep.21492","article-title":"Sustained virological response to interferon\u2010alpha is associated with improved outcome in HCV\u2010related cirrhosis: a retrospective study","volume":"45","year":"2007","journal-title":"Hepatology"},{"issue":"5","key":"hep32341-bib-0018-20250824","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.jhep.2016.07.027","article-title":"High incidence of hepatocellular carcinoma following successful interferon\u2010free antiviral therapy for hepatitis C associated cirrhosis","volume":"65","year":"2016","journal-title":"J Hepatol"},{"issue":"5","key":"hep32341-bib-0019-20250824","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S1413-8670(10)70093-3","article-title":"Effect of sustained virologic response on the incidence of hepatocellular carcinoma in patients with HCV cirrhosis","volume":"14","year":"2010","journal-title":"Braz J Infect Dis"},{"issue":"5","key":"hep32341-bib-0020-20250824","doi-asserted-by":"crossref","first-page":"677","DOI":"10.3851\/IMP1807","article-title":"The course of esophageal varices in patients with hepatitis C cirrhosis responding to interferon\/ribavirin therapy","volume":"16","year":"2011","journal-title":"Antivir Ther"},{"issue":"1","key":"hep32341-bib-0021-20250824","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1053\/j.gastro.2016.03.036","article-title":"Effects of eradicating hepatitis C virus infection in patients with cirrhosis differ with stage of portal hypertension","volume":"151","year":"2016","journal-title":"Gastroenterology"},{"issue":"6","key":"hep32341-bib-0022-20250824","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.jhep.2020.07.025","article-title":"aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis","volume":"73","year":"2020","journal-title":"J Hepatol"},{"issue":"6","key":"hep32341-bib-0023-20250824","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1093\/cid\/ciw362","article-title":"Diabetes and cirrhosis are risk factors for hepatocellular carcinoma after successful treatment of chronic hepatitis C","volume":"63","year":"2016","journal-title":"Clin Infect Dis"},{"key":"hep32341-bib-0024-20250824","doi-asserted-by":"crossref","first-page":"S535","DOI":"10.1016\/S0168-8278(18)31325-4","article-title":"In hepatitis C patients with cirrhosis who achieve SVR with treatment, reduction in transient elastography measures does not translate to reduced risk of hepatocellular carcinoma: a prospective cohort study","volume":"68","year":"2018","journal-title":"J Hepatol"},{"issue":"10","key":"hep32341-bib-0025-20250824","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1111\/jgh.15538","article-title":"Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis\u2010related complications (Taiwanese chronic hepatitis C cohort)","volume":"36","year":"2021","journal-title":"J Gastroenterol Hepatol"},{"issue":"3","key":"hep32341-bib-0026-20250824","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.cgh.2010.10.036","article-title":"Long\u2010term outcome after antiviral therapy of patients with hepatitis C virus infection and decompensated cirrhosis","volume":"9","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"hep32341-bib-0027-20250824","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s00535-004-1519-2","article-title":"Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon","volume":"40","year":"2005","journal-title":"J Gastroenterol"},{"issue":"4","key":"hep32341-bib-0028-20250824","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.jhep.2017.10.033","article-title":"The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C and sustained viral response: role of the treatment regimen","volume":"68","year":"2018","journal-title":"J Hepatol"},{"issue":"5","key":"hep32341-bib-0029-20250824","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2019.07.033","article-title":"Increased risk for hepatocellular carcinoma persists up to 10 years after HCV eradication in patients with baseline cirrhosis or high FIB\u20104 scores","volume":"157","year":"2019","journal-title":"Gastroenterology"},{"issue":"8","key":"hep32341-bib-0030-20250824","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1111\/jvh.13295","article-title":"The impact of SVR from direct\u2010acting antiviral\u2013 and interferon\u2010based treatments for HCV on hepatocellular carcinoma risk","volume":"27","year":"2020","journal-title":"J Viral Hepat"},{"issue":"8","key":"hep32341-bib-0031-20250824","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1089\/jir.2017.0040","article-title":"High post\u2010treatment \u03b1\u2010fetoprotein levels and aspartate aminotransferase\u2010to\u2010platelet ratio index predict hepatocellular carcinoma in hepatitis C virus decompensated cirrhotic patients with sustained virological response after antiviral therapy","volume":"37","year":"2017","journal-title":"J Interferon Cytokine Res"},{"issue":"5","key":"hep32341-bib-0032-20250824","doi-asserted-by":"crossref","first-page":"808","DOI":"10.5009\/gnl15360","article-title":"Treatment response and long\u2010term outcome of peginterferon \u03b1 and ribavirin therapy in Korean patients with chronic hepatitis C","volume":"10","year":"2016","journal-title":"Gut Liv"},{"issue":"6","key":"hep32341-bib-0033-20250824","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/liv.13629","article-title":"Follow\u2010up of sustained virological responders with hepatitis C and advanced liver disease after interferon\/ribavirin\u2010free treatment","volume":"38","year":"2018","journal-title":"Liver Int"},{"issue":"2","key":"hep32341-bib-0034-20250824","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s40121-021-00441-7","article-title":"Comparison of the prognosis of decompensated cirrhosis in patients with and without eradication of hepatitis C virus","volume":"10","year":"2021","journal-title":"Infect Dis Ther"},{"issue":"2","key":"hep32341-bib-0035-20250824","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.dld.2018.10.014","article-title":"Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals","volume":"51","year":"2019","journal-title":"Dig Liver Dis"},{"issue":"12","key":"hep32341-bib-0036-20250824","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1111\/jvh.13186","article-title":"The dynamic effect of direct\u2010acting antiviral treatments on the risk of hepatocellular carcinoma in patients with cirrhosis and chronic hepatitis C","volume":"26","year":"2019","journal-title":"J Viral Hepat"},{"issue":"5","key":"hep32341-bib-0037-20250824","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.jhep.2019.01.005","article-title":"Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: relevance of non\u2010characterized nodules","volume":"70","year":"2019","journal-title":"J Hepatol"},{"issue":"4","key":"hep32341-bib-0038-20250824","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/apt.14427","article-title":"Interferon\u2010free therapy of chronic hepatitis C with direct\u2010acting antivirals does not change the short\u2010term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis","volume":"47","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"hep32341-bib-0039-20250824","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1093\/cid\/cit103","article-title":"Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV\/hepatitis C virus\u2013coinfected patients with compensated cirrhosis","volume":"56","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"15","key":"hep32341-bib-0040-20250824","doi-asserted-by":"crossref","first-page":"3810","DOI":"10.3390\/cancers13153810","article-title":"Risk factors for liver decompensation and HCC in HCV\u2010cirrhotic patients after DAAs: a multicenter prospective study","volume":"13","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"2","key":"hep32341-bib-0041-20250824","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.jhep.2020.03.035","article-title":"Hepatocellular carcinoma surveillance after hepatitis C virus eradication: is liver stiffness measurement more useful than laboratory fibrosis markers?","volume":"73","year":"2020","journal-title":"J Hepatol"},{"key":"hep32341-bib-0042-20250824","doi-asserted-by":"crossref","first-page":"S531","DOI":"10.1016\/S0168-8278(18)31315-1","article-title":"De novo hepatocellular carcinoma in patients with cirrhosis due hepatitis C virus infection after treatment with direct antiviral agents","volume":"68","year":"2018","journal-title":"J Hepatol"},{"issue":"7","key":"hep32341-bib-0043-20250824","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/jvh.13276","article-title":"Incidence of HCC in chronic hepatitis C patients with advanced hepatic fibrosis who achieved SVR following DAAs: a prospective study","volume":"27","year":"2020","journal-title":"J Viral Hepat"},{"issue":"11","key":"hep32341-bib-0044-20250824","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1111\/liv.14666","article-title":"GES: a validated simple score to predict the risk of HCC in patients with HCV\u2010GT4\u2010associated advanced liver fibrosis after oral antivirals","volume":"40","year":"2020","journal-title":"Liver Int"},{"issue":"6","key":"hep32341-bib-0045-20250824","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s12072-020-10105-2","article-title":"HCC risk post\u2010SVR with DAAs in East Asians: findings from the REAL\u2010C cohort","volume":"14","year":"2020","journal-title":"Hepatol Int"},{"issue":"6","key":"hep32341-bib-0046-20250824","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1007\/s10620-011-1621-2","article-title":"Eradication of hepatitis C virus reduces the risk of hepatocellular carcinoma in patients with compensated cirrhosis","volume":"56","year":"2011","journal-title":"Dig Dis Sci"},{"issue":"1","key":"hep32341-bib-0047-20250824","doi-asserted-by":"crossref","first-page":"20922","DOI":"10.1038\/s41598-020-77515-y","article-title":"Incidence and risk factors of hepatocellular carcinoma in patients with hepatitis C in China and the United States","volume":"10","year":"2020","journal-title":"Sci Rep"},{"issue":"8","key":"hep32341-bib-0048-20250824","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1177\/135965350601100811","article-title":"A sustained virological response to interferon or interferon\/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicenter study in Taiwan","volume":"11","year":"2006","journal-title":"Antivir Ther"},{"issue":"1","key":"hep32341-bib-0049-20250824","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/apt.15597","article-title":"Letter: a 5\u2010year long\u2010term follow\u2010up study after DAA treatment confirms a reduced HCC risk in a central European cohort of HCV patients with liver cirrhosis","volume":"51","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"hep32341-bib-0050-20250824","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1159\/000503074","article-title":"Long\u2010term follow\u2010up of advanced liver disease after sustained virological response to treatment of hepatitis C with direct\u2010acting antivirals: outcomes from a real\u2010world Portuguese cohort","volume":"27","year":"2020","journal-title":"GE Port J Gastroenterol"},{"issue":"12","key":"hep32341-bib-0051-20250824","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1111\/liv.15032","article-title":"Hepatocellular carcinoma risk in hepatitis C stage\u20103 fibrosis after sustained virological response with direct\u2010acting antivirals","volume":"41","year":"2021","journal-title":"Liver Int"},{"issue":"5","key":"hep32341-bib-0052-20250824","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jhep.2009.12.028","article-title":"Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis","volume":"52","year":"2010","journal-title":"J Hepatol"},{"issue":"13","key":"hep32341-bib-0053-20250824","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1097\/QAD.0000000000002959","article-title":"Kinetics of emergence of liver complications in HCV\u2010infected patients and advanced fibrosis, with and without HIV\u2010coinfection, after SVR","volume":"35","year":"2021","journal-title":"Aids"},{"issue":"30","key":"hep32341-bib-0054-20250824","doi-asserted-by":"crossref","first-page":"4887","DOI":"10.3748\/wjg.v19.i30.4887","article-title":"Histopathology of type C liver disease for determining hepatocellular carcinoma risk factors","volume":"19","year":"2013","journal-title":"World J Gastroenterol"},{"issue":"3","key":"hep32341-bib-0055-20250824","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/hep.23744","article-title":"Outcome of sustained virological responders with histologically advanced chronic hepatitis C","volume":"52","year":"2010","journal-title":"Hepatology"},{"issue":"2","key":"hep32341-bib-0056-20250824","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jhep.2018.03.009","article-title":"Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: a prospective population study","volume":"69","year":"2018","journal-title":"J Hepatol"},{"issue":"24","key":"hep32341-bib-0057-20250824","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1001\/jama.2012.144878","article-title":"Association between sustained virological response and all\u2010cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis","volume":"308","year":"2012","journal-title":"JAMA"},{"issue":"5","key":"hep32341-bib-0058-20250824","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.jhep.2018.07.024","article-title":"Development of models estimating the risk of hepatocellular carcinoma after antiviral treatment for hepatitis C","volume":"69","year":"2018","journal-title":"J Hepatol"},{"issue":"6","key":"hep32341-bib-0059-20250824","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1002\/hep.31500","article-title":"Hepatic fat\u2010genetic risk score predicts hepatocellular carcinoma in patients with cirrhotic HCV treated with DAAs","volume":"72","year":"2020","journal-title":"Hepatology"},{"issue":"11","key":"hep32341-bib-0060-20250824","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1002\/hep4.1228","article-title":"Morphometry confirms fibrosis regression from sustained virologic response to direct\u2010acting antivirals for hepatitis C","volume":"2","year":"2018","journal-title":"Hepatol Commun"},{"issue":"3","key":"hep32341-bib-0061-20250824","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/liv.13256","article-title":"Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers Fibrosis\u20104 score and aspartate aminotransferase\u2010platelet ratio index","volume":"37","year":"2017","journal-title":"Liver Int"},{"issue":"2","key":"hep32341-bib-0062-20250824","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/hep.25606","article-title":"A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis","volume":"56","year":"2012","journal-title":"Hepatology"},{"issue":"3","key":"hep32341-bib-0063-20250824","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/hep.22694","article-title":"Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5\u2010year follow\u2010up of 150 patients","volume":"49","year":"2009","journal-title":"Hepatology"},{"issue":"6","key":"hep32341-bib-0064-20250824","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.jhep.2017.07.025","article-title":"Hepatocellular carcinoma risk following direct\u2010acting antiviral HCV therapy: a systematic review, meta\u2010analyses, and meta\u2010regression","volume":"67","year":"2017","journal-title":"J Hepatol"},{"issue":"2","key":"hep32341-bib-0065-20250824","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/jvh.13215","article-title":"Hepatitis C virus eradication with direct\u2010acting antiviral improves insulin resistance","volume":"27","year":"2020","journal-title":"J Viral Hepat"},{"issue":"5","key":"hep32341-bib-0066-20250824","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/apt.15976","article-title":"Association between steatohepatitis biomarkers and hepatocellular carcinoma after hepatitis C elimination","volume":"52","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"hep32341-bib-0067-20250824","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/j.cgh.2018.12.018","article-title":"Cost effectiveness of hepatocellular carcinoma surveillance after a sustained virologic response to therapy in patients with hepatitis C virus infection and advanced fibrosis","volume":"17","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"hep32341-bib-0068-20250824","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jhep.2020.10.016","article-title":"HCC surveillance after SVR in patients with F3\/F4 fibrosis","volume":"74","year":"2021","journal-title":"J Hepatol"},{"issue":"2","key":"hep32341-bib-0069-20250824","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1053\/j.gastro.2004.11.018","article-title":"Prospective comparison of transient elastography, FibroTest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C","volume":"128","year":"2005","journal-title":"Gastroenterology"},{"issue":"5","key":"hep32341-bib-0070-20250824","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/jvh.13482","article-title":"Impact of direct\u2010acting antiviral regimens on mortality and morbidity outcomes in patients with chronic hepatitis C: systematic review and meta\u2010analysis","volume":"28","year":"2021","journal-title":"J Viral Hepat"},{"issue":"2","key":"hep32341-bib-0071-20250824","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.cgh.2009.10.026","article-title":"Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus\u2013related cirrhosis","volume":"8","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5 Pt 1","key":"hep32341-bib-0072-20250824","first-page":"329","article-title":"Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta\u2010analysis of observational studies","volume":"158","year":"2013","journal-title":"Ann Intern Med"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hep.32341","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hep.32341","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/10.1002\/hep.32341","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,24]],"date-time":"2025-08-24T23:02:12Z","timestamp":1756076532000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1002\/hep.32341"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,7]]},"references-count":70,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.32341","relation":{},"ISSN":["0270-9139","1527-3350"],"issn-type":[{"value":"0270-9139","type":"print"},{"value":"1527-3350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,7]]},"assertion":[{"value":"2021-11-20","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-04","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}